Biotech start-up Cradle BV has raised €5.4m in seed financing to design cell-factories with AI and scale bioprocesses much faster and cheaper.
Precision gene delivery remains one of the greatest challenges in modern medicine. A Basel-based biopharma company, Vector BioPharma, has accepted the challenge and, with cutting-edge technology from the University of Zürich, is developing a revolutionary new way to deliver the right genes to the right place at the right time. Vector BioPharma aims to be the pioneer in delivering future medicines with this technology, now under development in multiple areas of urgent medical need.
Microbial casein maker Standing Ovation SA has inked an exklusive collaboration with Bel Group, one of France’s biggest cheese-makers to bring its vegan cheese to the market.
EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395
Danish Novo Nordisk Foundation has invested in Plant2Food, a new open innovation hub for researchers and companies to develop plant-based foods.
At the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer.
As a late-stage investor focusing on the European bioeconomy, the ECBF is carefully assessing the maturity of any technology, but more important than maturity is the ability to reach commercial scale. What governs that scale-up, and how do we assess it? What role does the TRL score play, and what key questions do we ask? An excerpt into a framework.
CB21 Pharma Ltd announces that it entered a global strategic collaboration to combine
its leading expertise and clinical research program in phytocannabinoids with world-class
pharmaceutical strategic consulting and business development services of NorthStar Corporate Finance Ltd and Kru?ger Beteiligungs GmbH, forming a new company called CB21 R&D.
The 24th edition is showcasing almost 150 companies with detailed portraits in English on 300 colored pages: small and medium-sized companies with a focus on research and development as well as successful global players. The guide is the international business card of Germanys biotechnology industry.
German Neotiv GmbH hat closed a €10m seed financing to speed-up product launch of its early diagnosis app for Alzheimer’s disease